Last reviewed · How we verify
Giapreza (ANGIOTENSIN II)
Giapreza works by mimicking the action of angiotensin II to constrict blood vessels.
Giapreza is a vasoconstrictor medication developed by La Jolla Pharmaceutical Co, now owned by La Jolla Pharma. It targets the type-2 angiotensin II receptor to increase blood pressure in patients with vasodilatory shock. Giapreza was FDA-approved in 2017 and is currently patented. The medication is a small molecule that works by mimicking the action of angiotensin II to constrict blood vessels. It is used to treat vasodilatory shock in adult patients.
At a glance
| Generic name | ANGIOTENSIN II |
|---|---|
| Sponsor | La Jolla Pharma |
| Drug class | Vasoconstrictor [EPC] |
| Target | Type-2 angiotensin II receptor, Type-1 angiotensin II receptor, Type-1 angiotensin II receptor |
| Modality | Recombinant protein |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 2017 |
Mechanism of action
. Mechanism of Action. Angiotensin II raises blood pressure by vasoconstriction and increased aldosterone release. Direct action of angiotensin II on the vessel wall is mediated by binding to the G-protein-coupled angiotensin II receptor type on vascular smooth muscle cells, which stimulates Ca 2+/calmodulin-dependent phosphorylation of myosin and causes smooth muscle contraction.
Approved indications
Common side effects
- Thromboembolic events
- Deep vein thrombosis
- Thrombocytopenia
- Tachycardia
- Fungal infection
- Delirium
- Acidosis
- Hyperglycemia
- Peripheral ischemia
Key clinical trials
- Prognostic Interest of Vasorin in Septic Shock (NA)
- Angiotensin II in Liver Transplantation (PHASE2,PHASE3)
- Dysfunctional Renin-Angiotensin System in Septic Shock (PHASE4)
- Early Angiotensin II in the Emergency Department (PHASE4)
- A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. (PHASE2)
- Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control (NA)
- A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria (PHASE2)
- Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) (PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Giapreza CI brief — competitive landscape report
- Giapreza updates RSS · CI watch RSS
- La Jolla Pharma portfolio CI